Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: Oncogene. 2008 Apr 14;27(34):4702–4711. doi: 10.1038/onc.2008.109

Figure 3.

Figure 3

In vivo activity of BIBW 2992 in xenograft models. (a) Animals carrying tumors established from A431 cells were treated daily with BIBW2992 by oral gavage at indicated doses. Statistical analysis of the tumor volumes in each group was performed using one-way analysis of variance (Dunnett's multiple test) with P-values consistently below 0.01. (b) Immunohistochemical analysis of A431 tumor sections obtained 6 h after the last dose confirms in vivo modulation of phosphorylated EGFR and AKT by BIBW2992. (c) Animals carrying tumors established from NCI-N87 cells were treated daily with BIBW2992 or weekly with an intravenous bolus of 20 mg/kg trastuzumab and analysed as in a. (d) 14 days after NCI-N87 xenograft formation, animals carrying tumors were treated daily with BIBW2992 and analysed as in Figure 3a. (e) Animals carrying tumors established from H1975 cells were treated daily with BIBW2992, gefitinib, or lapatinib and analysed as in a.